FOR IMMEDIATE RELEASE

Catabasis Pharmaceuticals Invited to Present in a Webinar Hosted by Parent Project Muscular Dystrophy

CAMBRIDGE, MA, May 8, 2015 – Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, has been invited by Parent Project Muscular Dystrophy (PPMD) to present on the Company's upcoming MoveDMD trial. MoveDMD is a Phase 1 / 2 clinical trial of CAT-1004 for the treatment of boys with Duchenne muscular dystrophy (DMD) regardless of dystrophin mutation. The presentation will take place on Wednesday, May 13, from 1pm to 2pm ET. The webinar is intended for parents of boys with DMD to describe the MoveDMD trial design and provide enrollment guidance.

The webinar can be accessed by visiting www.readytalk.com and providing the participant code 9449985. The audio dial-in can be accessed by dialing 1.866.740.1260 and providing the access code 9449985.

About CAT-1004

CAT-1004 is an investigational drug that inhibits activated NF-kB, a protein that coordinates cellular response to muscular damage, stress and inflammation and plays an important role in muscle health. In skeletal muscle, activated NF-kB drives muscle degeneration and suppresses muscle regeneration. In animal models of DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and degeneration and increased muscle regeneration. In Phase 1 clinical trials in adults, CAT-1004 inhibited NF-kB and was well tolerated with no observed safety concerns. Catabasis Pharmaceuticals plans to initiate patient enrollment in a Phase 1 / 2 clinical trial of CAT-1004, the MoveDMD trial, for the treatment of DMD in the second quarter of 2015.

About Catabasis

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company's focus is on treatments for rare diseases. The Company is also

developing other product candidates for the treatment of serious lipid disorders. For more information on the Company's technology and pipeline of drug candidates, please visit www.catabasis.com.

###

Corporate and Media Contact
Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com